Guggenheim Initiates Coverage on Danaher (NYSE:DHR)

Stock analysts at Guggenheim began coverage on shares of Danaher (NYSE:DHR) in a report released on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $275.00 price target on the conglomerate’s stock. Guggenheim’s target price indicates a potential upside of 20.32% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Raymond James lowered their price objective on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Wells Fargo & Company assumed coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $288.21.

Danaher Stock Performance

Shares of NYSE DHR opened at $228.55 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $165.08 billion, a P/E ratio of 43.62, a P/E/G ratio of 4.33 and a beta of 0.83. Danaher has a 12 month low of $222.53 and a 12 month high of $281.70. The stock has a 50 day moving average of $243.07 and a 200-day moving average of $256.49.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. As a group, equities research analysts predict that Danaher will post 7.5 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in Danaher in the 2nd quarter worth about $25,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher in the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the third quarter valued at approximately $40,000. FSA Wealth Management LLC bought a new position in Danaher in the 3rd quarter valued at approximately $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter worth approximately $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.